Please ensure Javascript is enabled for purposes of website accessibility

What's Causing Juno Therapeutics Shares to Tumble 11.9% Today

By Todd Campbell – Dec 11, 2017 at 2:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are selling shares following an important presentation at a key industry conference.

What happened

After the company presented data on its chimeric antigen receptor T-cell therapy (CAR-T), JCAR017, at the annual American Society of Hematology conference over the weekend, Juno Therapeutics (JUNO) shares are losing 11.9% of their value at 2 p.m. EST Monday.

So what

Juno Therapeutics reported arguably best-in-class safety for JCAR017 in non-Hodgkin lymphoma at the conference, but investors appear disappointed that response rates weren't higher.

A man staring at a screen showing a declining share price holds his head in his hands.

IMAGE SOURCE: GETTY IMAGES.

To be clear, JCAR017's efficacy has been solid, and the latest data show that it still matches up well against Novartis (NVS 0.48%) and Gilead Sciences (GILD 0.98%) CAR-Ts, Kymriah and Yescarta, respectively. All three of these gene therapies re-engineer a patient's T-cells so that they can better find and destroy cancer cells  -- and in trials, all three therapies have delivered impressive response rates at the three-month and six-month marks.

In JCAR017's case, the overall response rate in patients receiving the dose level that's being studied in the company's ongoing pivotal study was 74% at three months. The complete response rate for these patients was 68% at three months and 50% at six months.

Overall, 80% of patients receiving any dose of JCAR017 in the study who were in a complete response at three months stayed in complete response at six months. Also, 92% of patients in response at six months were still in response at the cutoff date for the data presentation.

It's bad science to compare these findings with findings from Novartis and Gilead Sciences' separate trials, but in my opinion, JCAR017 stands its ground with its competitors based on those figures. 

Where JCAR017 really shined was in its safety, though. Across the entire study, only one of 91 patients experienced severe cytokine release syndrome (CRS), a potentially life-threatening condition that's been common in CAR-T studies. Additionally, only 12% experienced severe neurotoxicity, another common adverse event that's been witnessed at higher rates in studies evaluating Yescarta and Kymriah.

Now what

If the response rates had separated significantly from the rates reported by Gilead Sciences and Novartis, then it would have been a slam-dunk presentation. Nevertheless, the trial appears to be a success, and if results are confirmed in the company's ongoing pivotal trial, then Juno Therapeutics could end up with the best-in-class CAR-T on the market because of its safety advantages. Data from JCAR017's pivotal trial are expected in 2018.

Initially, CAR-Ts are being evaluated in relapsing or refractory patients for whom there are limited treatment options, but over time, studies could prove that they're effective earlier in treatment, too. If so, then the ability to deliver high-rate response suggests they'll be standard care -- and given their six-figure price tags, that represents a multibillion-dollar market opportunity to Juno Therapeutics and its competitors.

Todd Campbell owns shares of Gilead Sciences. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Juno Therapeutics Inc. Stock Quote
Juno Therapeutics Inc.
JUNO
Gilead Sciences Stock Quote
Gilead Sciences
GILD
$86.26 (0.98%) $0.84
Novartis Stock Quote
Novartis
NVS
$87.71 (0.48%) $0.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.